Rebecca Y. Linfield

Rebecca Y. Linfield

Auto-generated profile, based on publicly available information

Rebecca Y. Linfield

Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2024 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
RLRebecca Y. Linfield
Rebecca Y. Linfield
NNNancy N. Nguyen
Nancy N. Nguyen
OLOlivia H. Laprade
Olivia H. Laprade
MHMark Holodniy
Mark Holodniy
ACAarthi Chary
Aarthi Chary
People with HIV are living longer due to advances in antiretroviral therapy. With improved life expectancy comes an increased lifetime risk of comorbid conditions - such as cardiovascular disease and cancer - and polypharmacy. Older adults, particularly those living with HIV, are more vulnerable to drug interactions and adverse effects, resulting in negative health outcomes. Antiretrovirals are involved in many potential drug interactions with medications used to treat common comorbidities and geriatric conditions in an aging population of people with HIV. We review the mechanisms and management of significant drug-drug interactions involving antiretroviral medications and non-antiretroviral medications commonly used among older people living with HIV. The management of these interactions may require dose adjustments, medication switches to alternatives, enhanced monitoring, and considerations of patient- and disease-specific factors. Clinicians managing comorbid conditions among older people with HIV must be particularly vigilant to side effect profiles, drug-drug interactions, pill burden, and cost when optimizing treatment. To support healthier aging among people living with HIV, there is a growing need for antiretroviral stewardship, multidisciplinary care models, and advances that promote insight into the correlations between an individual, their conditions, and their medications.

1 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKSooyeol Kim
Sooyeol Kim
AZAlessandro Zulli
Alessandro Zulli
ECElana M. G. Chan
Elana M. G. Chan
DDDorothea Duong
Dorothea Duong
RLRebecca Y. Linfield
Rebecca Y. Linfield
APAmy J. Pickering
Amy J. Pickering
Antibiotic resistance is a growing public health threat, with over 2.8 million antibiotic-resistant infections and 35,000 attributable deaths annually in the U.S. Here, we sought to use wastewater monitoring to assess community-level burden of antibiotic resistance. This study quantifies concentrations of antibiotic resistance genes (ARGs) by digital droplet PCR in wastewater solids obtained from 163 wastewater treatment plants in 40 states in the United States. We measure 11 ARGs that confer resistance to beta-lactams ( bla CMY , bla CTX-M , bla KPC , bla NDM , bla OXA-48 , bla TEM , bla VIM ), colistin ( mcr-1 ), methicillin ( mecA ), tetracycline ( tetW ), and vancomycin ( vanA ). The South has higher overall ARG concentrations compared to the Midwest. We pair these data with national data sets including antibiotic use, social vulnerability, size of animal agriculture operations, location of healthcare facilities, and presence of airports to investigate potential drivers of resistance. We also generate predictive maps of ARG concentrations for counties with data within the range of our training set in the United States. We show social vulnerability indicators (housing burden and access to health insurance) and indicators of international travel are associated with increased ARG concentrations in wastewater, while antibiotic usage is only weakly positively associated. Our results provide a national baseline of ARG concentrations and highlight the complexity of factors driving spread of antibiotic resistance.

10 November 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
RLRebecca Y Linfield
Rebecca Y Linfield
EGEva Gorenburg
Eva Gorenburg
JLJane Liang
Jane Liang
GNGuillermo Rodriguez Nava
Guillermo Rodriguez Nava
VKVanessa El Kamari
Vanessa El Kamari
JPJulie Parsonnet
Julie Parsonnet
Background: Cases of coccidioidomycosis are increasing dramatically in the U.S. The utility of intrathecal (IT) amphotericin in treating coccidioidal meningitis (CM) in the era of azole therapy is unknown. We sought to understand how IT therapy is associated with mortality. Methods: We conducted a retrospective chart review of adult patients with laboratory-proven CM seen at Stanford Healthcare by an Infectious Diseases physician from 2008-2023. Results: 57 patients met inclusion criteria. All patients received azole therapy. Twenty-seven of those patients (47.4%) additionally received IT amphotericin. Patients receiving IT therapy had had a higher median initial CSF WBC at diagnosis (462.5 vs. 188, p = 0.05), higher rates of IV liposomal amphotericin use (88.9% vs. 56.7%, p = 0.02) and corticosteroid use (51.9% vs. 26.7%, p = 0.09), and higher median therapeutic switches per year (0.84 vs. 0.44, p = 0.01). An unadjusted Kaplan-Meier curve demonstrated a five-year mortality rate of 26.7% in the IT amphotericin group, compared to 6.7% in non-receiver group, p = 0.28. A Cox regression revealed that older age at diagnosis (HR 1.07, 95% CI 1.03-1.11), receipt of IT amphotericin (HR 13.9, 95% CI 1.93-100.48), and corticosteroid use (HR 8.3, 95% CI 1.92-35.4) were significantly associated with mortality, with a significant interaction between IT amphotericin and corticosteroids (interaction HR 0.14, 95% CI 0.02-0.97). Conclusions: Patients who received IT amphotericin had higher mortality rates than those who did not, likely reflecting disease refractory to treatment. More therapies are needed for those who have disease progression on azole therapy.

1 January 2025 in Annals of Internal Medicine
Verified
Journal Article
Closed access
RLRebecca Y. Linfield
Rebecca Y. Linfield
LMLeon S. Moskatel
Leon S. Moskatel

18 July 2025 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
RLRebecca Y. Linfield
Rebecca Y. Linfield
LMLeon S. Moskatel
Leon S. Moskatel
SCSean Carlton
Sean Carlton
FAFatemeh Amrollahi
Fatemeh Amrollahi
DEDavid Epstein
David Epstein
LSLisa Shieh
Lisa Shieh

18 December 2025 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
LMLeon S. Moskatel
Leon S. Moskatel
RLRebecca Y. Linfield
Rebecca Y. Linfield
DSDavid J.G. Slusky
David J.G. Slusky
Utilizing aggregated, US electronic medical record data at the state level, we found that increased mpox incidence was associated with increased bacterial sexually transmitted infection (STI) rates in men for the same month and higher STI rates after the second mpox vaccination. Those seeking vaccination or testing for mpox should be screened for other STIs.